

ONE HUNDRED FIFTEENTH CONGRESS
Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927

Minority (202) 225-3641

August 4, 2017

Ms. Erin Bliss
Assistant Inspector General
Office of Evaluation and Inspections, Office of Inspector General
U.S. Department of Health and Human Services
330 Independence Avenue, S.W.
Washington, DC 20201

Dear Ms. Bliss:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, July 18, 2017, to testify at the hearing entitled "Examining HRSA's Oversight of the 340B Drug Pricing Program."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Friday, August 18, 2017. Your responses should be mailed to Ali Fulling, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to Ali.Fulling@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Tim Murphy
Chairman
Subcommittee on Oversight and Investigations

cc: The Honorable Diana DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachment

Attachment—Additional Questions for the Record

The Honorable Michael C. Burgess

1. The Office of the Inspector General found in its report “State Efforts to Exclude 340B Drugs from Medicaid Managed Care Rebates” that states can support efforts to prevent duplicate discounts from Medicaid Managed Care in the program through examining claims and exercising their own respective oversight of the program. The uptake, however, in this oversight has varied across the country. What incentives, if any, exist that would encourage the states to exercise oversight of the program?